IL2RA
Interleukin-2 receptor subunit alpha
As of the edition of 20 October 2026, IL2RA (interleukin-2 receptor subunit alpha, UniProt P01589) has 12 drugs tested at it and 14 companies on the list, 3 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01589
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 10
- Disease areas
- Cancer; Skin and connective tissue; Immune system; Urinary and reproductive; Blood and lymph; Pregnancy and women's health; Infections; Hormones
- Registered trials of its drugs
- 823
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 3 |
| Withdrawn from market | 1 |
| Status not established | 2 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Aldesleukin | Marketed | Phase 4 | Ended 2005 |
| Basiliximab | Marketed | Phase 4 | Ended 2010 |
| Daclizumab | Withdrawn from market | Phase 4 | Ended 2009 |
| Denileukin diftitox | Marketed | Phase 4 | Ended 2011 |
| BIIB019 | Went quiet | Phase 3 | none listed |
| LMB-2 | Status not established | Phase 2 | none listed |
| Camidanlumab tesirine | Stopped | Phase 2 | none listed |
| Inolimomab | Status not established | Phase 3 | none listed |
| MDNA11 | Active | Phase 2 | none listed |
| PF-08046032 | Stopped | Phase 1 | none listed |
| RM-1995 | Stopped | Phase 1 | none listed |
| Teceleukin | Marketed | No phase stated | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 3 |
| Engaged | 1 |
| Undetermined | 7 |
| Total on the list | 14 |
The other 11 companies at IL2RA
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at IL2RA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.